Development of microalbuminuria in essential hypertension

Current Hypertension Reports

Volumn 8, Issue 2, 2006, Pages 171-177

  Redon, Josep ^a   Pascual, Jose M ^b  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE;

ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR RISK; DISEASE MARKER; ENDOTHELIAL DYSFUNCTION; ESSENTIAL HYPERTENSION; FOLLOW UP; GLOMERULUS FILTRATION; GLUCOSE METABOLISM; HEREDITY; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; KIDNEY DISEASE; MEMBRANOUS GLOMERULONEPHRITIS; MICROALBUMINURIA; NEPHROSCLEROSIS; OBESITY; PATHOPHYSIOLOGY; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; SMOKING; STATISTICAL SIGNIFICANCE;

ALBUMINURIA; HUMANS; HYPERTENSION;

EID: 33744503654     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-006-0015-x     Document Type: Article

References (69)

1. Mogensen CE: Microalbuminuria predicts clinical proteinuria and early mortality in maturity onset diabetes. N Engl J Med 1984, 310:356-360.
2. Yudkin JS, Forrest RD, Jackson CA: Microalbuminuria as a predictor of vascular disease in non-diabetic subjects. Islington Diabetes Survey. Lancet 1988, 2:530-533.
3. Damsgaard EM, Froland A, Jorgensen OD, Mogensen CE: Microalbuminuria as predictor of increased mortality in elderly people. BMJ 1990, 300:297-300.
4. Haffner SM, Stern MP, Kozlowski MK, et al.: Microalbuminuria. Potential marker for increased cardiovascular factors in non-diabetic subjects? Atherosclerosis 1990, 10:727-731.
5. Bigazzi R, Bianchi S, Baldari D, Campese VM: Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J Hypertens 1998, 16:1325-1333.
6. Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, et al.: Urinary albumin excretion. An independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol 1999, 19:1992-1997.
7. Jager A, Kostense PJ, Ruhe HG, et al.: Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: five-year follow-up of the Hoorn Study. Arterioscler Thromb Vasc Biol 1999, 19:617-624.
8. Roest M, Banga JD, Janssen WM, et al.: Excessive urinary albumin levels are associated with future cardiovascular mortality in postmenopausal women. Circulation 2001, 103:3057-3061.
9. Gerstein HC, Mann JF, Yi Q, et al.: Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. HOPE Study Investigators. JAMA 2001, 286:421-426.
10. Romunstad S, Holmen J, Hallan H, et al.: Microalbuminuria and all-cause mortality in treated hypertensive individuals. Does sex matter? The Nord-Trondelag Health Study (HUNT), Norway. Circulation 2003, 108:2783-2789.
11. Wachtell K, Ibsen H, Olsen MH, et al.: Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: The LIFE Study. Ann Intern Med 2003, 139:901-906.
12. Guidelines Committee: 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003, 21:1011-1053.
13. Chobanian AV, Bakris GL, Black HR, et al.: National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289:2560-2572.
14. Ljugman S: Microalbuminuria in essential hypertension. Am J Hypertens 1990, 3:956-960.
15. Nosadini R, Semplicini A, Fioretto P, et al.: Sodium-lithium countertransport and cardiorenal abnormalities in essential hypertension. Hypertension 1991, 18:191-198.
16. Erley CM, Risler T: Microalbuminuria in primary hypertension: Is it a marker of glomerular damage? Nephrol Dial Transplant 1995, 9:1713-1715.
17. Bigazzi R, Bianchi S: Microalbuminuria as a marker of cardiovascular and renal disease in essential hypertension. Nephrol Dial Transplant 1995, 10(Suppl 6):10-14.
18. Cerasola G, Cottone S, D'Ignoto G, et al.: Microalbuminuria as a predictor of cardiovascular damage in essential hypertension. J Hypertens 1989, 7(Suppl 6):S332-S333.
19. Minram A, Ribstein J, DuCailar G: Is microalbuminuria a marker of early intrarenal vascular damage in essential hypertension? Hypertension 1994, 23:878-883.
20. Pedrinelli R, Giampietro O, Carmassi F, et al.: Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet 1994, 344:14-18.
21. Minram A, Ribstein J: Hyperfiltration in lean essential hypertension. Karger Basel. Contrib Nephrol 1996, 119:98-102.
22. Konen JC, Shihabi ZK, Summerson JH: Urinary transferrin and albumin excretion in patients with mild to moderate and controlled hypertension. Clin Physiol Biochem 1993, 10:1-7.
23. Alli C, Lombardo M, Zanni D, et al.: Albuminuria and transferrinuria in essential hypertension. Effects of anti-hypertensive therapy. Am J Hypertens 1996, 9:1068-1076.
24. Taddei S, Virdis A, Ghiadoni L, et al.: Endothelial dysfunction in hypertension. J Nephrol 2000, 13:205-210.
25. Sommers SC, Melamed J: Renal pathology of essential hypertension 1990, 3:583-587.
26. Yoshioka T, Shiraga H, Yoshida Y, et al.: "Intact nephrons" as the primary origin of proteinuria in chronic renal disease. Study in the rat model of subtotal nephrectomy. J Clin Invest 1988, 82:1614-1623.
27. Ruilope LM, Alcazar JM, Hernandez E, Rodicio JL: Long-term influences of antihypertensive therapy on microalbuminuria in essential hypertension. Kidney Int 1994, 45(Suppl 45):S171-S173.
28. Sievert-Delle A, Ljungman S, Hartford M, Wikstrand J: Effect of 14 years of antihypertensive treatment on renal function and urinary albumin excretion in primary hypertension. Am J Hypertens 1996, 9:841-849.
29. Bigazzi R, Bianchi S, Baldari D, Campese VM: Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J Hypertens 1998, 16:1325-1333.
30. Redon J, Rovira E, Miralles A, et al.: Factors related to the occurrence of microalbuminuria during antihypertensive treatment in essential hypertension. Hypertension 2002, 39:794-798.
31. Giaconi S, Levanti C, Fommei E, et al.: Microalbuminuria and casual and ambulatory blood pressure monitoring in normotensives and in patients with borderline and mild essential hypertension. Am J Hypertens 1989, 2:259-261.
32. Gerber LM, Smukler C, Alderman MH: Differences in urinary albumin excretion rate between normotensive and hypertensive, white and nonwhite subjects. Arch Intern Med 1992, 152:373-377.
33. Redon J, Lozano JV, Liao Y, et al.: Factors related to the presence of microalbuminuria in essential hypertension. Am J Hypertens 1994, 7:801-807.
34. Martinez MA, Moreno A, Aguirre de Carcer A, et al.: Frequency and determinants of microalbuminuria in mild hypertension: a primary-care-based study. MAPA - Madrid Working Group. J Hypertens 2001, 19:319-326.
35. Bianchi S, Bigazzi R, Valtriani C, et al.: Elevated serum insulin levels in patients with essential hypertension and microalbuminuria. Hypertension 1994, 23(Part 1):681-687.
36. Redon J, Miralles A, Pascual JM, et al.: Hyperinsulinemia as a determinant of microalbuminuria in essential hypertension. J Hypertens 1997, 15:79-86.
37. Fernandez-Llama P, Poch E, Oriola J, et al.: Angiotensin converting enzyme I/D polymorphism in essential hypertension and nephroangiosclerosis. Kidney Int 1998, 53:1743-1747.
38. Chaves FJ, Pascual JM, Rovira E, et al.: Angiotensin II AT1 receptor gene polymorphism and microalbuminuria in essential hypertension. Am J Hypertens 2001, 14:364-370.
39. de Jong PE, Verhave JC, Pinto-Sietsma SJ, Hillege HL: Obesity and target organ damage: the kidney. PREVEND Study Group. Int J Obes Relat Metab Disord 2002, 26 (Suppl 4):S21-S24.
40. Pinto-Sietsma SJ, Mulder J, Janssen WM, et al.: Smoking is related to albuminuria and abnormal renal function in nondiabetic persons. Ann Intern Med 2000, 133:585-591.
41. Opshal JA, Abraham PA, Haltenson ChE, Keane WF: Correlation of office and ambulatory blood pressure measurements with urinary albumin and N-acetyl-beta-D-glucosaminidase excretions in essential hypertension. Am J Hypertens 1988, 1:117S-120S.
42. Lurbe E, Redon J, Pascual JM, et al.: Altered blood pressure during sleep in normotensive subjects with type 1 diabetes. Hypertension 1993, 21:227-235.
43. Redon J, Miralles A, Liao Y, et al.: Circadian variability and microalbuminuria in essential hypertension. J Hypertens 1994, 12:947-954.
44. Redon J, Lurbe E: Ambulatory blood pressure and the kidney. In Calcium Antagonists in Clinical Medicine, edn 3. Edited by Epstein M. Philadelphia: Hanley and Belfus; 2002:665-681.
45. Groop L, Ekstrand A, Forsblom C, et al.: Insulin resistance, hypertension and microalbuminuria in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1993, 36:642-647.
46. Nosadini R, Solini A, Velussi M, et al.: Impaired insulin-induced glucose uptake by extra-hepatic tissue is hallmark of NIDDM patients who have or will develop hypertension and microalbuminuria. Diabetes 1994, 43:491-499.
47. Agewall S, Fagerberg B, Attvall S, et al.: Microalbuminuria, insulin sensitivity and haemostatic factors in non-diabetic treated hypertensive men. The Risk Factor Intervention Study Group. J Intern Med 1995, 237:195-203.
48. Nestler JE, Barlascini GO, Tetrault GA, et al.: Increased transcapillary escape rate of albumin in nondiabetic men in response to hyperinsulinemia. Diabetes 1990,39:1212-1212
49. Bigazzi R, Bianchi S, Baldari D, et al.: Microalbuminuria in salt-sensitive patients: a marker for renal and cardiovascular risk factors. Hypertension 1994, 23:195-199.
50. Nesovic M, Stojanovic M, Nesovic MM, et al.: Microalbuminuria is associated with salt sensitivity in hypertensive patients. J Human Hypertens 1996, 10:573-576.
51. Campese VM: Salt sensitivity in hypertension: renal and cardiovascular implications. Hypertension 1994, 23:531-550.
52. Weir MR, Dengel DR, Behrens MT, Goldberg AP: Salt-induced increases in systolic blood pressure affect renal hemodynamics and proteinuria. Hypertension 1995, 25:1339-1344.
53. Erley CM, Holzer M, Kramer BK, Risler T. Renal hemodynamics and organ damage in young hypertensive patients with different plasma renin activities after ACE inhibition. Nephrol Dial Transplant 1992, 7:216-220.
54. Pontremoli R, Sofia A, Tirotta A, et al.: The deletion/insertion polymorphism of the angiotensin I-converting enzyme gene is associated with target organ damage in essential hypertension. J Am Soc Nephrol 1996, 7:2550-2558.
55. Yudkin JS, Andres C, Mohamed AV, et al.: The angiotensin-converting enzyme gene and the angiotensin II type I receptor gene as a candidate genes for microalbuminuria. A study in non-diabetic and non-insulin dependent diabetic subjects. Arterioscl Thromb Vasc Biol 1997, 17:2188-2191.
56. Jeunemaitre X, Soubrier F, Kotelevtsev YV, et al.: Molecular basis of human hypertension role of angiotensinogen. Cell 1992, 71:169-180.
57. Sato N, Katsuya T, Rakugi H, et al.: Association of variants in critical core promoter element of angiotensinogen gene with increased risk of essential hypertension in Japanese. Hypertension 1997, 30:321-325.
58. Inoue I, Nakajima T, Williams CS, et al.: A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro. J Clin Invest 1997, 99:1786-1797.
59. Bakker SJ, Gansevoort RT, Stuveling EM, et al.: Microalbuminuria and C-reactive protein: similar messengers of cardiovascular risks? Curr Hypertens Rep 2005, 7:379-384.
60. Barzilay JI, Peterson D, Cushman M, et al.: The relationship of cardiovascular risk factors to microalbuminuria in older adults with and without diabetes mellitus or hypertension: the cardiovascular health study. Am J Kidney Dis 2004, 44:25-34.
61. Pedrinelli R, Dell'Omo G, Di Vello V, et al.: Low-grade inflammation and microalbuminuria in hypertension. Arterioscler Thromb Vasc Biol 2004, 24:2414-2419.
62. Stuveling EM, Bakker SJ, Hillege HL, et al.: C-reactive protein modifies the relationship between blood pressure and microalbuminuria. PREVEND Study Group. Hypertension 2004, 43:791-796.
63. Schrier RW, Estacio RO, Esler A, Mehler P: Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002, 61:1086-1097.
64. Lurbe E, Redon J, Kesani A, et al.: Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med 2002, 347:797-805.
65. Redon J: Renal protection with antihypertensive drugs. Insights from the microalbuminuria studies. J Hypertens 1998, 16:2091-2100.
66. Pascual JM, Rodilla E, Gonzalez C, et al.: Long-term impact of systolic blood pressure and glycemia on the development of microalbuminuria in essential hypertension. Hypertension 2005, 45:1125-1130.
67. Redon J, Chaves FJ, Liao YL, et al.: Influence of the I/D polymorphism of the angiotensin-converting enzyme gene on the outcome of microalbuminuria in essential hypertension. Hypertension 2000, 35:490-495.
68. Marin P, Julve R, Chaves FJ, et al.: Polymorphisms of the angiotensinogen gene and the outcome of microalbuminuria in essential hypertension: a 3-year follow-up study. J Human Hypertens 2004, 18:25-31.
69. Agewall S, Wikstrand J, Ljugman S, et al.: Does microalbuminuria predict cardiovascular events in nondiabetic men with treated hypertension? The Risk Factor Intervention Study Group. Am J Hypertens 1995, 8:337-342.